Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8620776 | 0.89 | S1PR1 (0.46) | S1PR1S1PR3MTNR1AFDFT1S1PR4 | |
| SCHEMBL8620506 | 0.83 | S1PR1 (0.50) | S1PR1S1PR3FDFT1S1PR4S1PR5 | |
| SCHEMBL8624761 | 0.83 | S1PR1 (0.44) | S1PR1S1PR3FDFT1S1PR4S1PR5 | |
| SCHEMBL8618716 | 0.80 | PLA2G4A (0.40) | MTNR1ATHRAPLA2G4AGGPS1 | |
| SCHEMBL8947035 | 0.80 | PLA2G4A (0.40) | MTNR1ATHRAPLA2G4AGGPS1 | |
| SCHEMBL8623396 | 0.79 | FFAR1 (0.45) | FDFT1 | |
| SCHEMBL8659011 | 0.78 | FDFT1 (0.56) | S1PR1S1PR3FDFT1S1PR4S1PR2 | |
| SCHEMBL8624285 | 0.77 | FDFT1 (0.37) | S1PR1S1PR3FDFT1S1PR4S1PR5 | |
| SCHEMBL8619655 | 0.76 | FDFT1 (0.44) | FDFT1 | |
| SCHEMBL27768842 | 0.76 | MEN1 (0.50) | THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |